Results of the Royal Marsden Hospital second soft tissue sarcoma schedule (STS II) chemotherapy regimen in the management of advanced sarcoma.
Forty-eight patients with advanced soft tissue sarcoma were treated with a five-drug combination regimen consisting of vincristine, actinomycin D, and cyclophosphamide (Day 1) followed by doxorubicin and an infusion of methotrexate (Day 22). Thirty-seven of the 48 patients were fully evaluable. Of the 37 evaluable patients, two achieved a complete remission and three achieved a partial remission, with an overall response rate of 13.5%. These results compare unfavorably with previously reported series from this and other centers, and the regimen has now been superseded.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000401:mortality; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate